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Abstract
Ketamine is a derivative of phencyclidine with unique anesthetic, analgesic, as 
well as antidepressant pharmacological properties. Despite its clinical use, ketamine 
is classified on the list with new psychoactive substances having psychedelic prop-
erties. The abuse trend of ketamine increasing globally, and it became a common 
club drug over the past few decades. Of note, recreational use of ketamine may pose 
a threat to public health, leading to numerous physical, as well as psychiatric nega-
tive effects. In addition, simultaneously or sequentially ketamine use with other 
drugs, resulting in serious health consequences. Currently, there are no specific 
treatment options for managing compulsive drug-seeking behavior in patients with 
ketamine use disorder, while the pharmacotherapy of side effects is limited and 
mostly symptomatic. In this chapter, we discuss ketamine abuse history. Further, 
we proposed the mechanisms of neural disinhibition underlying addiction develop-
ment in ketamine-dependent patients. We have also included details of possible 
negative consequences focusing on long-term and recreational ketamine use for 
both, central and peripheral systems. Finally, we provide an overview of ketamine 
concomitant use and corresponding adverse interactions.
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1. Introduction
Ketamine has long been known as a potent anesthetic drug with analgesic 
properties, however, it quickly evolved into a recreational drug in the early 1980s 
[1]. The first use of ketamine as a drug was recorded in 1965 [2]. Widespread, 
nonmedical uses of ketamine expanded through that time due to sub-cultures began 
experimented with the drug for mind exploration the inner psyche, and New Age 
spiritualism.
Ketamine is also known as the ‘club drug’ and since the mid-1980s, it has been 
linked to a variety of dance cultures, because of its trance-like state potency. That 
also explained why teenagers and young adults (16 to 25 years) are the people who 
are most susceptible to ketamine abuse. Ketamine is known by various names, by 
clubbers usually called “K”, “vitamin K”, “super K”, or “special K” [3, 4]. In the 
United States of America as well as in the United Kingdom ketamine was used as 
an adulterant in methylenedioxy-methamphetamine (MDMA) under the name of 
“horse pill” [5].
The typical ketamine users are regular visitors of the electronic dance music 
scene [6]; psychonauts; injecting heroin users, and the ‘gay’ club/party scene [7]. 
In addition, according to the data from the Crime Survey for England and Wales 
(CSEW) for 2012/2013, it is usually single male, aged 20–24, unemployed or study-
ing, and from Chinese or mixed-race ethnic roots [8].
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The most important reasons for ketamine’s recreational use are as follows: short 
time to effect; duration of action (up to 3 h), as well as low cost. Ketamine was 
gained popularity as a party drug due to the appearance of powerful psychoactive 
effects even at low, subanesthetic (0.1–0.5 mg/kg) doses [9]. As a dissociative anes-
thetic, ketamine and other drugs such as phencyclidine (PCP) or dextromethorphan 
(DXM), distort the user’s perception of sight and sound, while producing illusions of 
detachment from the environment or body, known as a „falling into a K-hole” (near-
death experience). This state is also associated with the lack of the ability to speak 
and move around easily, not accompanied by actual loss of consciousness [10]. It is 
considered that; ketamine had the highest degree of out-of-body experiences among 
any other drugs, like a bad LSD trip. While not all ketamine users had out-of-body 
experiences, less than 10% of subjects experience this phenomenon regularly [11]. 
Of note, these symptoms can be prolonged and even create psychosis associated 
with schizophrenic and other psychotic disorders. In fact, ketamine has been used 
experimentally to develop a ‘ketamine model’ of psychosis [12, 13].
Additionally, hallucinations, emotional withdrawal, and “melting into the sur-
rounding” may occur. It is also very likely for users (at very high doses of ketamine 
or those combining ketamine with alcohol or other drugs) to experience numbness, 
amnesia, more intense dissociations, and delirium [14].
Ketamine’s ability to induce confusion, amnesia and alter some of the perceptual 
effects make this drug a so-called “date rape drug”. For this reason, ketamine was 
included in the Drug-Induced Rape Prevention Act of 1966 [15]. Unfortunately, 
some of the symptoms and side-effects are long-lasting (i.e., impairment to episodic 
and possibly attentional functioning). Although semantic memory impairments 
are thought to be reversible as a consequence of ketamine cessation or substantial 
reduction of its use [9, 16].
2. Epidemiology of ketamine illicit use
The recreational use of ketamine has climbed over decades in the UK [17, 18], 
Australia [7], Southeast Asian countries such as Taiwan, Malaysia, and China,  
particularly such phenomenon was reported among the youth and adolescents 
[19–22]. It could be, in part, due to ketamine’s lower status in regulatory systems and 
lower price, compared to still expensive “ecstasy” or methamphetamine. In Hong 
Kong, where ketamine was classified as a Schedule I drug since 2000, ketamine 
became the most commonly misused drug in the early 2000s [21].
The abuse of ketamine has been declining over the past years but is still relatively 
common. According to the national survey-based ‘Monitoring the Future Study’ in the 
United States ketamine ingestion decreased between 2002 and 2012 from 2.5% to 1.5%, 
and from 1.3% to 0.4%, among 12th graders and college students, respectively [23].
The decreasing ketamine popularity was also noticed in the United Kingdom 
(UK), where it has been classified on the list as a Class C drug since 2006 [21], and 
then was reclassified as a Class B drug from 10 June 2014 [24]. The World Health 
Organization fact file has demonstrated the ketamine usage in the UK decreased 
from 0.6% to 0.4% and from 1.8% to 0.8%, respectively, between 2011 and 2013 
[23]. Similarly, in another study the level was continued to fall in 2013 to 50.6% 
and 31.5%, but these were still higher than for US respondents (26.3% and 15.4%, 
respectively) [25].
Before the COVID-19 pandemic global last year use rates of ketamine were 
6.72% in 2016, 8.6% in 2017 and 6.5% in 2018; lifetime rates for 2017 and 2018 
were 11.7% and 10.4%, respectively [26, 27]. During the COVID-19 pandemic 
state, a reduction in ‘party drugs’-like ketamine consumption was expected. As the 
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limited access to pubs, clubs, and festivals cancelation were the primary reasons 
for decreases in the recreational use of illicit drugs which are typically linked to 
the nightlife and party scenes. In fact, in Australia, the use of ecstasy/MDMA and 
related drugs (e.g., cocaine, ketamine) had fallen compared to the pre-pandemic 
level [28, 29]. The less interest in club drugs like ketamine was also noticed by 
Neutravel, an Italian non-governmental organization (NGO) [30].
Surprisingly, in the U.S. according to the national survey-based ‘Monitoring 
the Future Study’, it has been demonstrated the ketamine use raised between 2019 
and 2020 from 0.7 to 1.3% respectively among 12th graders [31]. Some individuals 
paradoxically start to use ketamine due to anxiety caused by the pandemic time, 
while others increased its consumption during lockdown spent at home. [32].
3. Ketamine status in the regulatory systems
In 1999, ketamine including its salts, isomers, become a Schedule II non-narcotic 
substance under the Federal Controlled Substances Act in the U.S. This means that 
the drug does have lower misuse potential but is still approved for use in hospitals 
and other medical settings as an anesthetic. Because of this, it is illegal to possess 
ketamine without a medical reason, prescription, or as a part of the research. Thus, 
the illicit use of ketamine appears to be from illegal diversion from legal prescription, 
but analogs which usually contain a range of undeclared psychoactive substances 
(i.e., amphetamine, benzocaine, cocaine, MDMA, methoxetamine, paracetamol, 
piperazines, and synthetic cathinones) may also be found on the streets [33].
Nowadays, in the U.S., ketamine is classified as a schedule III drug under the 
DEA Controlled Substances Act. Medications in this category are often used for 
pain control, or anesthesia, or appetite suppression. It means that ketamine has less 
potential for abuse than Schedule I (heroin) or Schedule II (cocaine) drug, and it is 
not as tightly regulated as most opioids. However, abuse of Schedule III substances 
may lead to moderate or low physical dependence but more commonly leads to high 
psychological dependence. This means that for users outside the approved limits, its 
adverse mental and physical health effects can be hazardous [34].
Ketamine has been revived a couple of times in 2003, 2006, and 2012 by The 
Expert Committee on Drug Dependence of the World Health Organization (WHO), 
and finally, it has remained on the list as an essential medicine. The experts con-
sidered that the international control is not appropriate in this case, as new facts 
about ketamine were not sufficient to warrant scheduling. In the recent World 
Drug Report by United Nations Office on Drugs Control 2019 (UNOD 2019) [35], 
ketamine is classified under new psychoactive substances (NPSs), which are not 
under the control of international drug conventions, but which may pose a threat 
to public health. Since 2000, in the European Union, ketamine is not under the 
control, however further monitoring of drug use is recommended by the European 
Commission. Despite the increasing trends of abuse, dependence, and dying from 
ketamine recreational use, its status did not change significantly over time. It seems 
to be still relatively low, especially when compared with other Novel Psychoactive 
Substances (i.e., synthetic cannabinoids and cathinones or ‘designer benzos’). This 
raises important concerns about the underestimation of ketamine.
4. Methods of ketamine abuse
The route of ketamine administration is crucial for the type and the intensity of 
the experience the effect. Ketamine has a dose–response curve with variable effects 
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(Table 1). However, unlike other psychedelic drugs like LSD, ketamine triggers a 
short trip, lasting no more than 1.5 hours. The illicit product mostly involves evapo-
rating the liquid from the diverted injectable solution to produce a dry powder that 
is formed into tablets or sold as a powder. The most common method of ketamine 
abuse is “snorting” and 96% of ketamine users choose such a way for its useful-
ness and rapid action noticed in roughly 5 to 10 minutes [33]. In comparison, oral 
consumption requires between 15 and 20 minutes (Table 2) [25]. For nonmedical 
use, a typical intranasal dose is 50 mg and the oral dose is 100 mg [38, 39], but the 
usual recreational dose range between 60 and 250 mg of ketamine [40]. Ketamine 
abusers will often self-administer several sequential doses of the drug to maintain 
psychotropic effects over time. However, an injection results in the most rapid 
effect (within seconds to minutes), though such a way of administration is quite 
difficult especially in clubs. Interestingly, a recent animal study has revealed that 
a high IV ketamine dose caused the complete cessation of cortical EEG activity for 
several minutes, similarly to the ‘K-hole’ in humans [41]. Recently, online user fora, 
as well as research findings, also support vaping as a possible route of ketamine 
administration [42, 43].
5.  The central and peripheral consequences of long-term and 
recreational ketamine misuse
There are no medical uses in which ketamine is provided chronically. The 
majority of reported long-term effects of ketamine are those which have devel-
oped in chronic recreational users or animals during preclinical studies. Although 
controlled human studies of repeated doses of ketamine are prohibited because 
it would be unethical to give an anesthetic with pronounced adverse effects more 
often. In clinical settings, ketamine is rather well tolerated. Although the pattern of 
Single dose [mg]* Route Onset of action [min] Duration of action [min]
75–125 i.m. 1–5 30–45
60–250 i.n. 5–10 45–60
50–100 i.v. seconds 30–45
200–300 p.o. 15–20 60–120
Abbreviations: intramuscular (i.m.); insufflation, intranasal or “snorting” (i.n.); intravenously (i.v.), per os, orally 
“by mouth” (p.o).*Typical recreational dose is 10–25% of the effective general anesthetic dose [37].
Table 2. 
Ketamine recreational dose ranges, the routes of administration, onset and duration of action ([36] with some 
modifications).
Dose range [mg] Related effects
Low: 10–75 mild euphoria, feeling of well-being, feelings of calmness and relaxation, empathy, 
smell, and tastes muted, visual hallucinations, enhanced color vision, sense of touch 
deterioration
Medium: 60–125 slow motion, auditory hallucinations (ringing in the ears), detached feeling from the 
body, loss of coordination, diminished reflexes
High: 100–250 felling light, timelessness, body dysmorphia, ‘K-hole’ out-of-body experiences
Table 1. 
The common effects of ketamine in snorted doses.
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adverse effects of non-medical ketamine use may differ from that expected from 
prescribed medical use. In individuals who misuse ketamine, serious sequelae, 
including prolonged neuro-, urological-, and gastro-toxicity may occur. The 
residual effects which may persist beyond acute ketamine dosing and its long-
term consequences have been compiled and presented in the following subsec-
tions below.
5.1 Psychosis
Evidence of the psychotogenic potency of ketamine initially emerged from 
general anesthetic use where clinicians noted drug- related post-anesthetic reac-
tions (i.e., confusion, vivid dreams, and hallucinations) leading to a reduction in 
the clinical drug utility [9, 44, 45].
There are some evidences that infrequent and frequent ketamine users exhibited 
higher levels of schizophrenia-like, dissociative, and depressive symptoms [13]. 
Hansen et al. [46] described the most common subjective effects of ketamine in 
recreational users including the sensation of light through the body; novel experi-
ences concerning “body consistency” (e.g., being made of wood, rubber, or plastic); 
unreal shape or size of body parts; a sensation of floating or hovering in a weightless 
condition; timeless; sudden insight into the self; the experience of being at one with 
the universe; an experience of leaving the body; visions and hallucinations).
Subanesthetic doses of ketamine in healthy volunteers also trigger positive and 
negative schizophrenic-like symptoms as well as perceptual alterations similar to 
dissociative states with altered body perception, depersonalization, derealization, 
and distorted sensory perception. Of note, ketamine had the highest degree of out-
of-body experiences compared to the other drugs as was mentioned in the previous 
section. While it is given to chronic, stable schizophrenics, ketamine has been 
shown to cause a re-emergence of the acute phase of the illness [47].
Ketamine exerts its unique behavioral effects mostly by blocking the NMDA 
receptors [48, 49]. Although phencyclidine (PCP; “angel dust”) has a 10-fold 
greater affinity for the NMDA receptor and is more excitotoxic than ketamine. 
Over the past several decades many animal models have been developed using drug 
mimics endogenous deficits in NMDA receptor function to study the mechanism 
of schizophrenia [48]. The cumulative effect of repeatedly using ketamine and/or 
a residual effect has occurred 3 days after abusers took this drug [50]. More impor-
tantly, even strong schizophrenic-type symptoms and perceptual distortions may 
persist after cessation of ketamine use [17, 36].
One of the explanations of such effect is NMDA receptor dysfunction even 
several days after acute use. Second, a residual effect may also be psychological in 
that ketamine produces an intensely subjective experience that could affect users’ 
perceptions of the world for several days after it is taken [13, 50].
5.2 Cognitive deficits
There is increasing evidence that regular and long-lasting ketamine use can induce 
central nervous system depression and impair cognition, in particular visual and 
verbal memory as well as executive function [50–52]. The frequent ketamine users 
with increasing drug doses were more likely to have cognitive deficits, especially 
with short- and long-term spatial working memory and pattern recognition memory 
tasks [53]. Short-term memory and visual memory deficits occur usually in users who 
abused the drug at least 4 days per week. Similarly, according to findings from animal 
studies, ketamine seems to deteriorate memory at relatively high doses. Short-term 
memory and spatial memory were impaired in rats administered 30 mg/kg i.p. 
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and were revealed by the delayed spatial alternation task and finding to the hidden 
platform in the Morris water maze test [54, 55].
Interestingly, ketamine appears to have greater potency to reduce cognition than 
other drugs of abuse [13]. These cognitive deficits may affect functioning in the 
abuser’s daily life due to difficulty in remembering conversations and other people’s 
names [13]. It has been also found that men to be more affected by these effects than 
women [56]. In addition, cognitive deficits are also related to the impairment of the 
psychomotor performance, such as coordination, balance, and hand-eye movements. 
This lack of coordination may cause the inability to drive or operate machinery, 
thereby increasing accidental injury or even mortality from motor vehicle collisions. 
Data from an epidemiological study involving drug-related motor vehicle collision 
fatalities found 9% related to ketamine use, representing a disproportionate number 
of fatalities compared to alcohol and opioid misuse [57].
In 2007, according to data from a single trauma centre in Hong Kong roughly 
4.5% of drivers involved in non-fatal crashes tested positive for ketamine [58].
In addition, ketamine may gradually change the brain’s chemical system affect-
ing opioids, dopamine (it activates dopamine systems), serotonin, noradrenaline, 
nitric oxide, sigma, GABA (gamma amino-butyric acid), and acetylcholine, among 
others [59, 60].
Ketamine has been also induced electrophysiological dissociation between the 
thalamo-neocortical and limbic systems and potentiated the synaptic inhibition 
of GABA [36, 61, 62]. However, the key pharmacological mechanisms underlying 
ketamine-related cognitive deficits are mediated via an NMDA glutamate receptors 
hypofunction [4]. There have been also shown that NMDA antagonists’ potency 
induced degeneration in a subset of limbic structures like those which are altered in 
patients with psychoses [63]. Animal studies revealed that direct apoptotic neu-
rodegeneration was induced by NMDA-R antagonists, including ketamine, in the 
developing rodent brain. However, this ketamine effect was more evident in older 
rats [64]. According to other findings from animal studies the racemic ketamine 
(with its preservative benzethonium chloride) and S-ketamine have been associated 
with neuronal apoptosis and sensorineural consequence following high dose and/or 
long-term i.v. administration [65–68]. However, translatability to humans is ques-
tioned and the impact of lower subanesthetic doses is uncertain.
In this way, ketamine abuse may display structural damage in multiple brain 
areas, such as the frontal, occipital, parietal, limbic, and corpus striatum [69, 70].
There have been shown that such detrimental effect is related to time and the 
dose of ketamine abuse [69]. Data have also revealed that the brain atrophies may 
occur within 1 year of ketamine intensive use with expected further progression in 
the following years [70]. In fact, ketamine dose reduction may restore cognition, 
but we cannot rule out irreversible and residual effects [17, 50].
As data have demonstrated NMDA receptors must be blocked for at least 
24 hours to produce irreversible effect or death in the cells, but ketamine has a short 
half-life (about 20 minutes in rats) thus many injections are needed, over a pro-
longed period, to produce persistent change [71].
Although we have still limited data regarding cognitive ability from the ketamine 
ex-user population to provide straightforward conclusions for these findings. To 
date, there is no specific pharmacotherapy to avoid cognitive deficits in long-term 
ketamine use. The management of these problems is largely supportive and symp-
tomatic. The cognitive enhancers are taken into consideration, such as modafinil, 
commonly used in stimulant addiction, as well as cholinesterase inhibitors (i.e., 
rivastigmine, donepezil, galantamine) usually recommended in other disorders 
with cognitive impairments (i.e., Alzheimer’s disease, Parkinson’s disease, traumatic 
brain injury, and schizophrenia), among others [51, 72].
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5.3 Pro-depressant effect
Compared to growing evidence available for the anti-depressant effect of ket-
amine, there is still less for its pro-depressant potency [73]. Ironically, an intranasal 
ketamine formulation was recently approved in the USA, and Europe to treat 
intractable depression and acute suicidal ideation [74]. The depressive potency of 
ketamine seems to be dose and time-related. Insights from the animal study indicate 
that the antidepressant action at a dose of 10 mg/kg was not observed in rats receiv-
ing a higher dose of ketamine (80 mg/kg) [75]. Likewise, the anti-depressive effects 
linked to the subanesthetic ketamine dose (0.5 mg/kg) might not correspond to the 
same effect at the dosages range, preferred by recreational users. It was suggested 
that an opposite pro-depressant effect may be linked to certain neuroadaptation 
changes [76]. In fact, some studies demonstrated that chronic use of ketamine 
causes more lasting depressive effects [4, 36, 53]. There have been shown that ket-
amine abusers reported depressive symptoms quite common, roughly 72.5%–77.5% 
of them were diagnosed with moderate to severe depression based on the Beck 
Depression Inventory scores [77, 78].
According to the results from various studies, the prevalence of major depressive 
disorder (MDD) in outpatient settings fluctuating between 7.8–18.5%, in compari-
son to inpatient populations with nearly one-fourth (23.3%) ketamine-dependent 
MDD comorbidity [79–81]. Though, according to certain authors, the mood 
measures revealed little and clinically insignificant difference between groups with 
slightly higher scores in the ketamine users [50].
Interestingly, increased depression scores have been found in both daily users 
and ex-users in a longitudinal study, although not more infrequent users [53]. The 
mechanism of the acute antidepressant and chronic depressant effects may be 
linked, but it is unclear exactly how this opposite effect is mediated. Why abstinent 
ketamine users were more depressed is also less clear but may be linked with a 
change in their lifestyle. In fact, the frequent ketamine users had experienced more 
negative life events over the 12 months, due probably to their chaotic lifestyles, 
which may also trigger depressive symptoms [82].
In addition, previous evidence indicates that the depressive symptoms in 
ketamine users may persist even for 1 year after abstinence [53]. Furthermore, 
increased depression in frequent users could also reflect their increased dependency 
on ketamine, as depression is also commonly comorbid in opiate- and alcohol-
dependent populations [83, 84]. Recent data imply that depression might be 
associated with craving (stronger propensity to administer more ketamine). There 
have been shown that patients with higher craving intensity demonstrated a greater 
severity of depression, longer history of ketamine administration, and greater use 
frequency than those with lower craving intensity [81].
5.4 Tolerance
Ketamine-induced tolerance may be considered in many aspects, although it is 
exceptionally mentioned in psychopharmacological clinical studies.
Firstly, ketamine is known as an effective anesthetic drug widely used in the 
clinic, however, as with many drugs, this effectiveness is often compromised due 
to tolerance to ketamine’s anesthetic effects, which might be of great importance 
especially when the patient has a history of drug abuse. Similarly, there are sev-
eral papers indicating tolerance to the antidepressive effects of ketamine during 
repeated administrations [85]. Nonetheless, tolerance to ketamine can develop 
rapidly in all species, including after one large dose [86, 87], or even in patients 
with major depressive disorder. A great example derived from the case study of 
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Bonnet [85] provided evidence that a continuous antidepressant response to daily 
ketamine injections can be followed by a swift return of a major depressive episode 
after cessation of ketamine. Other papers demonstrate animals chronically given 
ketamine that required increased doses of ketamine to reach the target anesthetic 
plane. Moreover, animals had a shorter duration of anesthesia [86, 88]. Surprisingly, 
rats pretreated with intraperitoneal morphine at a dose of 5.6 mg/kg demonstrated 
cross-tolerance to ketamine’s anesthetic effects [88].
5.5 Withdrawal
Ketamine, being a drug easily abused, may induce several uncomfortable 
adverse reactions as a consequence of its cessation. There is increasing evidence that 
ketamine causes psychological but not physical dependence. Withdrawal symptoms 
are usually like withdrawal from cocaine with very strong cravings. Symptoms 
of acute withdrawal may be short-lived and not identified as such [89]. However, 
the withdrawal from ketamine may paradoxically cause depression [90]. Other 
withdrawal symptoms after ketamine discontinuation include dysphoria, shaking, 
sweating, palpitations, tiredness, low appetite, low mood, chills, autonomic arousal, 
lacrimation, restlessness, anxiety, nightmares, paranoia, delusions, and hallucina-
tions [81, 91, 92]. Noteworthy, these withdrawal symptoms typically begin within 
24 h of discontinuation and last approximately 3 days, although in some cases, they 
may persist for 2 weeks and thereafter stabilize [93].
Apart from the abovementioned, there several reports are indicating that due to 
ketamine discontinuing mild forms of schizophrenic-like symptoms occur [17].
5.6 Ketamine-induced uropathy: “the ketamine bladder”
Recreational abuse of ketamine has been associated with bladder pain  
syndrome; ulcerative cystitis also known as ‘ketamine bladder’. Up to a quarter 
of ketamine, abusers may experience such problems. According to the European 
Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance 
database about 23% and 17% of ketamine-related adverse drug reactions (ADR) 
respectively referred to renal/urinary disorders. Interestingly, such issues being 
more common among women than men [94]. In general, urological problems occur 
within 1 month-1 year time frame following the start of ketamine use, but recent 
pharmacovigilance data revealed that even an acute ketamine administration may 
be associated with urological risks, as in some cases the risk was noticed within 
48 hours of treatment [94].
Initially, ketamine associate bladder disturbance may mimic common conditions 
such as urine infections and it may be difficult to diagnose, but further urinary 
symptoms may substantially disturb the quality of the abuser’s life thus extreme 
individuals have difficulty with passing urine. There are reports of needing to 
pass urine up to 20 times an hour, leading to hydronephrosis and finally kidney 
failure [4].
Damage to the urinary barrier initiates bladder pain and, in ketamine-induced 
cystitis, loss of urothelium from large areas of the bladder wall was reported [95]. 
Ketamine abuse also induces small bladder volume, bladder wall thickening, and 
mucosal enhancement. The most common ketamine bladder symptoms reported 
in the 2018 Global Drug Survey were as follows: urine frequency 38%; pain in the 
abdomen 25%; burning when urinating 18%; incontinence 7%; and blood 3% [96].
The first report of the urological syndrome was published in 2007 by Shahani 
and colleagues [97]. The cause of urinary toxicity appears to be multifactorial and 
not fully explained. It is postulated that the direct toxic effect of ketamine or its 
9
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active metabolite (norketamine) on the urinary tract may play a crucial role [98]. 
It is also pointed out, that the urinary toxicity seems to be unrelated to ketamine 
interaction with NMDA receptors (NMDAR). Thus, in vitro studies revealed that 
normally human urothelial cells were unresponsive to NMDAR agonists or antago-
nists, and no expression of NMDAR transcript was detected [95].
A recent study offers new evidence for a mechanism of direct toxicity of 
ketamine to the urothelial by activating the intrinsic apoptotic pathway. In fact, 
exposure to ketamine in noncytotoxic concentrations initiates the transient release 
of calcium Ca(2+) from the endoplasmic reticulum into the cytosol. However, 
ketamine concentrations >1 mmol/L become cytotoxic and provokes a larger-
amplitude increase in cytosolic Ca(2+) concentration. Consequently, sustained 
elevation in Ca(2+) leads to pathological mitochondrial oxygen consumption and 
ATP deficiency, and it initiates damage to the urinary barrier [95].
The chronic immune response of the bladder interstitial cells may be another 
possible underlying mechanism of toxicity [99, 100]. Biopsies have also revealed 
epithelial denudation, eosinophilic, as well as mast cell infiltration [97, 101]. 
Ketamine may also trigger interstitial fibrosis by damaging the papillary medullary 
interstitial cells [98]. There are also reports of metaplasia in the intestine related 
to ketamine abuse [102]. Furthermore, ketamine through its central action may 
disturb the contractile response of smooth muscle from appropriate stimuli [103].
In addition, ketamine may induce highly destructive microvascular changes 
causing epithelial-to-mesenchymal transition, which finally contributes to bladder 
or kidney fibrogenesis [100, 104].
Compared to the urinary tract, renal damage and bilateral hydronephrosis are 
less frequent but may also occur. Chronic kidney failure may develop as the final 
consequence of a long-term sequel [105].
Of note, there a no specific and casual pharmacotherapy for ketamine-related 
urinary tract disorder. The symptomatic treatment with antibiotics, anti-inflam-
matory agents, steroids, and anticholinergics in most cases has failed [106]. In such 
a scenario, the second line of alternative treatment with intravesical agents such 
as hyaluronic acid, and injections of Botulinum toxin-A should be considered. 
Preclinical studies have also suggested a future therapy with combined intravesical 
liposomal onabotulinum toxin-A instillation and mesenchymal stem cells placed 
directly into the bladder submucosal layer [107]. However, the urinary problems 
may improve and became reversible if ketamine use is reduced/withdrawn, thus 
ketamine abstinence should be the first step in ketamine-induced uropathy treat-
ment. The abstinence greater than 3 months is related to some improvement and 
less severe symptoms. Of note, in some cases, urological issues may persist for up to 
1 year after ketamine abstinence [108]. More invasive methods, such as a catheter 
(tube into the bladder), urinary diversion, and nephrectomy may be required in 
the prolonged ketamine abuse and irreversible renal damage which may produce a 
burden to healthcare resources [100, 102, 103].
5.7 Gastrointestinal pathology: ‘K cramps’
Regular and long-term ketamine use is associated with gastric pathology of 
unknown etiology, colloquially termed ‘KCramps’ [37, 98].
In line with the 2010 Mixmag Survey, ‘K cramps’ occurred in 30% of ketamine 
users and was a more common issue among women [109]. The persistent epigastric 
pain is classified as the commonest upper GI symptoms as was presented in 73% of 
abusers after a higher dose, daily ketamine use [110]. Among symptoms that were 
also frequently diagnosed in ketamine users are cystic dilatations of the common 
bile duct, in association with abnormal liver function tests [111–113].
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In a retrospective study of GI symptoms followed by inhalational ketamine use, 
28/37 of the subjects experienced upper GI symptoms. The mean time of ketamine 
use was 4 years before admission. Exclusion criteria included potential risk factors 
and a history of GI disorder. The most common finding was epigastric pain only, 
which occurred in 23 (62.2%) users. Four users had epigastric pain with vomiting. 
In sporadic cases, gastroduodenitis, and intestinal metaplasia have occurred. More 
importantly, all symptoms relief with abstinence from ketamine use [110]. Of note, 
pains symptomatology related to GI in ketamine users may resemble irritable bowel 
syndrome as in some parts tend to be triggered by psychological changes [37, 114].
There has been shown that gastric pathology among ketamine users correlated 
with the duration of drug use [111, 115]. The exact mechanism by which ketamine 
produces cholestasis and biliary dilation is unclear but is a possible direct link to 
NMDA receptor blockade in smooth muscle. In addition, ketamine may also act 
through the dorsal motor nucleus of the vagus, projecting to the gall bladder [116].
Effective treatment of GI toxicity includes discontinuation of ketamine use 
which can lead to the relief of symptoms, otherwise, treatment options are 
nonspecific [110].
Of note, there are certain cases of evidence of causal risk between chronic 
ketamine use and GI toxicity as dilated common bile duct regressed with abstinence 
but recurred following a return to ketamine use [111].
6. Ketamine and other substances/drugs adverse reactions
The phenomenon of interaction is used in clinical practice as multi-drug 
therapy. Its aim is to increase the pharmacological potency and obtain desired 
therapeutic effect while reducing doses of individual drugs. Such steps reduce the 
likelihood of side effects and are beneficial for the patient. However, the problem 
arises when unwanted drug interactions occur, and this includes i) pharmaceutical 
interactions, i.e. incompatibilities arising outside the patient’s body; ii) pharma-
cokinetic interactions related to the fate of the drug in the body at the stage of its 
absorption, distribution, metabolism and excretion; and finally iii) pharmacody-
namic interactions, where one drug modifies the action of another drug.
All these benefits as well as undesired interactions are true for ketamine and 
other substances. Use with multiple drugs has been fatal.
Firstly, ketamine (both its R(−)- and S(+)-enantiomers) undergoes hepatic 
biotransformation through the cytochrome P450 (CYP450), particularly with the 
involvement of CYP2B6 and CYP3A4, to form norketamine. Therefore, an altera-
tion of CYP450 metabolism results in clinically significant drug–drug interactions 
that can further cause unanticipated adverse reactions and/or therapeutic failures. 
For instance, drugs that induce both these cytochrome isoforms may reduce 
exposure to ketamine. In contrast, substances inhibiting CYP enzymes can lead 
to an increase the exposure to the drug. As a great example is the treatment with 
diazepam, being a substrate of CYP3A4, which increases ketamine plasma half-life, 
thus its sedative effects [117, 118]. On the other hand, ketamine can also influence 
diazepam metabolism as its decreases CYP3A4 enzyme activity [119].
Apart from the involvement of CYP 450 isoforms in the metabolism of  
ketamine, also another hepatic phase II enzymes may be taken under consideration. 
Indeed, ketamine has been shown to inhibit UGT2B7 and thus the metabolism of 
morphine both in vitro and in vivo [120, 121], therefore increases the liver con-
centration of the opioid. Intriguingly, also the brain concentration of morphine 
is found to increased (three- to five-fold 90 min after administration). However, 
such drug concentration changes in the brain are not because of changes at the 
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blood–brain barrier as it was compared with oxycodone mainly metabolized by 
cytochrome P450 (CYP) enzymes [122]. Also, when considered oppositely,  
morphine, but not oxycodone, pretreatment increased the brain and serum  
concentrations of ketamine [123].
CYP3A4 enzyme is known to be affected by compounds derived from grapefruit 
juice or whole fruit (i.e., furanocoumarins and, to a lesser extent, flavonoids) [124]. 
Therefore, in the case of ketamine given orally, a significant increase in plasma 
concentration can be found in healthy volunteers [125].
Unfortunately, drug metabolism via CYP450 enzymes exhibits also genetic 
variability (polymorphism), thus in this case also some variations in the exposure 
to ketamine are obvious. Poor metabolizers of enzymes metabolizing ketamine are 
extremely rare. However, the paper of Rao et al. [126] provided with information 
that CYP2B6*6 polymorphism variant did not affect single, low-dose ketamine 
metabolism, clearance, and pharmacokinetics in healthy human volunteers, though 
diminished ketamine metabolism in vitro.
Concerning pharmacodynamic interaction once should be said that the nature 
of ketamine-drug interactions together with the observable effect is highly depen-
dent on the drug type and thus the molecular target (i.e., opioidergic system, 
dopaminergic, serotoninergic, etc.) as well as from the dose used. There is a great 
several papers characterizing possible pharmacodynamics interactions between 
ketamine and different drugs both natural and synthetic. For instance, estrogen 
together with progesterone potentiated ketamine-induced antidepressant effect 
[127], while BNN27, a synthetic derivative of dehydroepiandrosterone reduced 
ketamine-induced ataxia [128]. Ketamine was found to produce additive effects 
when combined with gamma-aminobutyric acid (GABA) activity. This was found 
true for barbiturates such as thiopental at a hypnotic endpoint [129], but not with 
a benzodiazepine - midazolam [130]. Also, for anesthesia induction, the combina-
tion of ketamine and midazolam was found additive rather than synergistic at the 
endpoint of loss of response to verbal command [130]. When introduced with other 
benzodiazepines (i.e., clonazepam, alprazolam, lorazepam), specifically for the 
treatment of long-lasting depression, as well as considering that both types of drugs 
act on interneurons, ketamine antidepressant efficacy was mute [131, 132]. This 
finding suggested that benzodiazepines inhibitory activity towards ketamine’s anti-
depressant effect may be related to attenuation of neuroplastic processes, emerging 
subsequently after the acute effect and after ketamine and its active metabolites are 
eliminated from the blood since benzodiazepines occurred ineffective in the first 
24 h post-concomitant administration of both drugs [131].
Analyzing other effects mediated by simultaneous ketamine and benzodi-
azepines, the following can be mentioned: (1) inhibition of ketamine-induced 
hyperlocomotion by diazepam [133]; (2) ketamine’s emotional stress reduction by 
a sub-hypnotic lorazepam [134]; (3) lorazepam intensification of ketamine seda-
tive effects [134]; (4) potentiation of ketamine amnestic action by diazepam and 
lorazepam [134, 135]; (5) antagonism of the cardiovascular effects of ketamine 
by diazepam [136], or (6) ketamine-induced emergence delirium prevented by 
midazolam [137]. Whereas concerning antipsychotics such as haloperidol it has 
been shown that it can reduce ketamine-induced cognitive impairment. In addition, 
haloperidol was found to attenuate the increase of locomotor activity and stereo-
typed behavior, reversed the motor incoordination, and blocked the hypermobility 
induced by acute administration of ketamine in rodents [138].
Yet another possible interaction occurs between ketamine and the opioid 
system, as ketamine (in particular (S)-ketamine) was characterized as a drug that 
partially interacts with the opioid system, particularly mu-opioid receptors [139]. 
Indeed, as already mentioned, ketamine enhances levels of morphine, which may 
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explain the long-lasting morphine-induced antinociception [120]. Importantly, the 
enhanced level of morphine is strictly associated with ketamine inhibitory activity 
towards morphine tolerance, which is mainly by N-methyl-d-aspartate (NMDA) 
receptor antagonism [121, 140]. On the other hand, it has long been suggested that 
opioids may enhance the antidepressant effect induced by ketamine, as naltrexone 
attenuated this activity [141]. However, currently, the involvement of the opioid 
system in this specific action is unclear since partial agonists (i.e., methadone and 
buprenorphine) did not influence ketamine’s antidepressant effect [142].
Opioids are well known for their great ability to induce respiratory depression, 
especially when overdosed. Intriguingly, also in this aspect, an interaction between 
ketamine and opioids exists. In fact, intraperitoneal (i.p.) administration of ket-
amine has led to significant respiratory depression in mice, but not in mu-opioid 
receptor knock-out mice [143].
As with other CNS medications, it should be mentioned that ketamine is capable 
of modifying effects mediated by alcohol consumption and illicit drugs. In the 
first case, it has been revealed that subjects simultaneously taking alcohol and 
ketamine are more vulnerable to suffer from the urinary tract and gastrointestinal 
problems such as pain with urination, increased frequency of urination, or even 
lower abdominal pain [144]. Of note, individuals with a family history of alcoholism 
with altered NMDA activity may have a blunted effect on the negative psychological 
reactions to ketamine. Whereas, as a great example of a drug of abuse, apart from 
the aforementioned opioids, for which a concomitant use with ketamine may result 
in unpredictable and extremely dangerous side effects is a so-called “liquid Extasy” 
[92, 145]. This compound is a gamma-hydroxybutyric acid (GHB), being a naturally 
occurring analog of gamma-aminobutyric acid (GABA), with esthetic and euphoric 
properties. Concerning ketamine, it has been shown that this drug together with 
GHB, in particularly high doses, results in an increased risk of respiratory depression 
and fatality. In addition, ketamine produced and enhanced GHB-mediated cataleptic 
effects in mice [146]. Also, can lead to a significant increase in sleep time.
Dangerous interactions were also noted for ketamine and methamphetamine 
both in vitro and in vivo. In fact, the co-exposure of these two drugs resulted in sig-
nificant cytotoxicity and synergy on oxidative stress in HepG2 cells [147]. While in 
mice treated with a low dose of methamphetamine and ketamine, the stress-related 
depressive and anxiety-related behavioral alterations caused by the psychostimu-
lant were antagonized consistently by both high and low doses of ketamine [148]. 
Furthermore, a combined repeated administration of both drugs was reported 
to increase significantly the risk of psychological dependence as shown in a rat 
conditioned place preference test [149]. In turn, in methamphetamine-dependent 
humans, a very high prevalence of psychotic disorders was suggested for those who 
occasionally or continuously use ketamine [150]. Moreover, when used with other 
stimulant drugs such as ecstasy, high blood pressure may appear [50]. Ketamine 
may be also toxic when is combined with caffeine. Theoretically, this may be a 
concern in people who have consumed energy drinks, especially at nightclubs where 
ketamine may be abused.
Ketamine is also a very popular drug taken together with cocaine. Unfortunately, 
such a combination occurred to result in a potentiation of cocaine-induced hepa-
totoxicity associated with sub-massive hepatic necrosis. These observations were 
indicated for rats pretreated with ketamine for three consecutive days at a dose of 
100 mg/kg with a single dose of cocaine (5 mg/kg, i.v.) [151]. This information is 
especially intriguing when compared with recent data demonstrated that a single 
ketamine infusion in cocaine abusers, coupled with a mindfulness behavioral 
modification program, seems to be a promise to achieve both the abstinence and 
reduction of the risk of relapse [152].
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Ketamine is known to be related to several molecular targets, either directly or 
indirectly. Indeed, due to its interactions with sodium channels (local anesthetic 
properties), i.e. L-type calcium channels and potassium channels [153], ketamine 
when administered with grapefruit juice may cause harmful effects ranging from 
relatively mild hypotension and dizziness. Furthermore, ketamine being an antago-
nist towards acetylcholinergic receptors produces various effects while interacting 
with cholinesterase and anticholinesterase agents. One great example is the interac-
tion with atropine which was found to slightly increase the ketamine-induced time 
of immobility in rats [154]. On the other hand, ketamine blocked the EEG and 
the behavioral toxic effects of neostigmine and physostigmine. While physostig-
mine can reverse the central anticholinergic effects and also antagonize ketamine 
hypnotic effects [155]. However, in the aspect of somnolence reverse, there are 
contradictory results. In fact, while Balmer [156] found physostigmine effective in 
reversing ketamine-induced somnolence. Drummond et al. [157] indicated phy-
sostigmine as ineffective in producing a rapid patient awaking or even in reducing 
hallucinatory behavior.
Another possible cellular target of ketamine includes the monoaminergic sys-
tem, particularly noradrenergic and serotonergic. Alpha2 agonists such as xylazine 
or medetomidine as well as dexmedetomidine were found safe when combining 
with ketamine [158]. Both these drugs were shown to reduce the dosage of ketamine 
and the occurrence of psychomotor symptoms after ketamine. As for compounds 
actin at serotonergic receptors of various types or being selective serotonin reup-
take inhibitors (SSRIs) it can be provided that repeated subanaesthetic doses of 
ketamine can redeem the time lag for the antidepressant-like effects of citalopram 
[159]. Also, such a combination given to rats resulted in a decrease in the immo-
bility time and increase in struggle time in the Forced Swim Test (FST) and Tail 
Suspension Test (TST) as compared to control group [160].
Beneficial effects were also observed for other serotonergic agents. For instance, 
intravenous ketamine emetic properties were inhibited by ondasteron in children 
[161]. Moreover, ketamine was reported to potentiate the anxiolytic effects of SSRIs 
such as fluoxetine [162].
Apart from the above-mentioned, also cannabinoids were indicated to be 
vulnerable to interact with ketamine. These includes delta 9-tetrahydrocannabinol  
being the major psychoactive molecule among synthetic cannabinoid ligands 
that act at cannabinoid 1 receptor (CB1), as well as cannabidiol (CBD) displaying 
potency as an antagonist of CB1 and CB1 receptor agonist, respetively. Indeed, 
Frizza et al. [163] reported 9-tetrahydrocannabinol to prolong the anesthesia 
induced by ketamine in mice. Whereas CBD was found reduced depersonaliza-
tion when administered with ketamine, as measured by the Clinical Administered 
Dissociative State Scale in healthy humans [164].
Overall, it can be noted that ketamine, possibly due to the complex mechanism 
of action, may interact with various molecular targets resulting in both critical and 
beneficial effects. Therefore, there is no unequivocal opinion as to whether ket-
amine should be used with caution or not; this depends strictly on the type of the 
second drug used as well as on other physiological and pathophysiological factors, 
including age, genetic polymorphism, and occurrence of diseases and disorders.
7. Conclusions
Non-medical, recreational use of ketamine has increased in certain populations/
sub-groups with geographical variations in its use patterns. Ketamine abuse seems 
to be an important public health challenge due to its association with multiple 
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physical and psychological harms. Noteworthy, the psychedelic effect may have a 
therapeutic value in some points and be harmful in others. Long term users may 
develop different neurobiological alterations, psychological dependency, with-
drawal, tolerance, schizophrenia-type symptoms, poor psychological well-being, 
memory difficulties, and finally worse quality of daily life. In the long-term use, 
there is also evidence of deleterious effects for the peripheral system, associated 
with serious lower urinary tract symptoms, and gastrointestinal pathology. In addi-
tion, polysubstance consumption is inherently risky and can lead to serious adverse 
consequences, especially when abusers mixing ketamine with eighter depressants or 
stimulants. Although of concern did not cause any significant changes in ketamine’s 
legal status over the years. There are numerous studies revealed the effects of a 
single administration of ketamine, thus the effects following repeated use and long-
term consequences are still less known and underestimated. More study is needed 
to better elucidate the real ketamine safety profile regarding both its long-term 
recreational use and its clinically use as an antidepressant agent.
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